Biosergen AB is a biotech company developing INNOVATIVE ANTIFUNGAL DRUGS based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway and several other places worldwide.
Biosergen AB is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.
Biosergen AB will aim BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS, cancer and transplant patients every year.
At equal dose levels BSG005 has demonstrated a 3 - 4 times potency advantage against the relevant fungal strains compared to the current standard of care, while being completely free of the kidney toxicity hampering other drugs in its class.